Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Neuroteg AI is based in Kasterlee, Belgium. Its website centers on concepts such as Envoy3D, Spatial-to-Spatial AI, and OncoHolo, arguing for a shift in how complex diseases—such as cancer, Alzheimer’s disease, Parkinson’s disease, and ALS—are understood: from traditional 2D perspectives to 3D spatial modeling. The focus is not merely on identifying individual lesions or biomarkers, but on analyzing how cells, blood vessels, immune infiltration, stroma, and metabolic processes interact in three-dimensional space.
Based on the site content, Envoy3D is described as a “dynamic 3D agent” capable of processing multi-source data such as the tumor microenvironment (TME), brain pathological infiltration, MRI/PET, and liquid biopsy data. It also uses multi-agent parallel analysis to examine different spatial regions or pathological mechanisms. Typical outputs include 3D TME maps, immune cell infiltration status, relationships between vasculature and tumor cores, potential drug resistance mechanisms, personalized immunotherapy pathways, and simulated clinical trial concepts based on digital twins and Digital Cousins.
The page does not provide any pricing, free trial, subscription plans, or commercial licensing information. It also does not explain API or SDK availability, deployment options, data formats, or PACS/EHR integration. Although the content mentions integration with MRI, PET, liquid biopsy, cfDNA, and genetic and epigenetic biomarkers, this reads more like a capability vision than evidence of a deliverable software product.
Its strengths lie in its forward-looking topic selection, especially its focus on the importance of 3D spatial relationships in the tumor microenvironment and neurodegenerative diseases. Its analytical framework for immunotherapy, drug delivery, vascular normalization, CAR-T navigation, and drug resistance prediction is relatively comprehensive, and the site also discloses several patent application numbers. The limitations are equally clear: there is a lack of model details, training data, clinical validation, accuracy metrics, regulatory certifications, and real hospital case studies. Much of the content remains conceptual and aspirational, and is not yet sufficient to demonstrate clinical readiness.
Neuroteg AI is better suited for early-stage research teams at pharmaceutical companies, tumor immunology researchers, medical imaging and spatial omics research groups, and teams exploring digital twin healthcare. It is not a good fit for organizations looking to immediately purchase a mature AI medical SaaS product, or those that require clear compliance certifications or standardized APIs.
Information on access from mainland China, payment methods, and local support has not been disclosed, so these remain unknown for now. If it is to be used in Chinese medical scenarios, key areas to verify include network accessibility, cross-border medical data compliance, clinical validation, and local alternatives.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on neuroteg.com official site.
neuroteg.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach neuroteg.com directly.